What Searchlight Pharma does

Searchlight Pharma is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec, that acquires, in-licenses, and commercializes branded pharmaceutical products across women's health, dermatology, pain management, neurology, allergy, and hospital specialty markets. Founded in 2015, the company built a portfolio of more than 65 branded products through a combination of organic launches, tuck-in acquisitions (notably Miravo Healthcare / Nuvo Pharmaceuticals in March 2023 and ERFA Canada 2012 in January 2022), and exclusive Canadian licensing agreements with international innovators including Grünenthal, Mithra Pharmaceuticals, Sol-Gel Technologies, Kissei Pharmaceutical, and Gedeon Richter. Its core technology approach is asset-light and centered on proprietary formulation platforms accessed through partnerships, exemplified by Sol-Gel's silica-based microencapsulation technology that underpins Twyneo (tretinoin + benzoyl peroxide for acne) and Epsolay (benzoyl peroxide for rosacea), both of which received FDA approval in the U.S. before being licensed into Canada.

Searchlight's revenue model blends branded product sales in Canada with licensing royalties and milestone payments from international partners. In Canada, products are commercialized through a flexible sales and marketing model targeting healthcare professionals and patients, distributed via pharmacy, hospital, and specialty channels. Internationally, the company monetizes Canadian-originated or owned intellectual property through outbound licensing (e.g., Suvexx licensed to Orion Corporation for all EU markets) and captures upfront fees, regulatory and sales milestones, and tiered royalties from inbound partners. Key revenue drivers include established women's health brands (Nextstellis, Evra, Haloette, Mona Lisa IUDs), dermatology assets (Epsolay), migraine therapy (Suvexx), and a late-stage pipeline anchored by DONESTA (menopause), Qutenza (neuropathic pain), Nebido (testosterone replacement), and linzagolix (uterine fibroids).

In June 2024, Apotex Inc., Canada's largest pharmaceutical company, completed the acquisition of Searchlight Pharma, which now operates as Apotex's Branded Medicines Division. The combination pairs Searchlight's specialty and innovative branded portfolio with Apotex's leadership in generic and biosimilar pharmaceuticals, distribution scale, and manufacturing capabilities (including the Varennes, Quebec production facility). The company has earned Globe and Mail Top Growing Companies recognition for five consecutive years (2019-2023), Miravo Healthcare (now a subsidiary) received the Globe and Mail Women Lead Here award for three consecutive years (2021-2023), and the combined entity maintains commercial operations across Canada with international operations through its Dublin-based Nuvo Ireland subsidiary.

Name

Searchlight Pharma

Legal name

Searchlight Pharma Inc.

Website

https://searchlightpharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Searchlight Pharma is Apotex's Branded Medicines Division, a Canadian specialty pharmaceutical company that in-licenses, develops, and commercializes branded prescription products across women's health, dermatology, pain, neurology, allergy, and hospital specialty markets for Canadian healthcare professionals and patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Specialty pharmaceuticals
• Branded medicines
• Women's health therapeutics
• Dermatology products
• Pharmaceutical commercialization

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Others

Revenue model

1. Branded Product Sales: Searchlight Pharma generates revenue through the sale and commercialization of its portfolio of branded specialty pharmaceutical products in Canada, including women's health, dermatology, allergy, neurology, pain management, and hospital specialty products. The company holds exclusive commercial and marketing rights for these products in Canada.
2. Licensing and Milestone Payments: As Apotex's branded medicines division, Searchlight enters into licensing agreements where partners receive upfront payments, regulatory milestone payments, and sales-based royalties. For example, the DONESTA agreement includes €1.5M upfront and up to €15.55M in regulatory and sales milestones plus royalties. Sol-Gel agreements include up to $11M in milestones plus 10-19% royalties on net sales.
3. International Licensing (Suvexx): Searchlight's subsidiary Nuvo Ireland holds intellectual property rights for Suvexx outside Canada. Orion Corporation launched Suvexx in Europe under a license and supply agreement, with upfront payments (€600K), launch payments (€400K), sales milestones, and royalties flowing back to Searchlight/Nuvo Ireland.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Searchlight Pharma is a Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes branded healthcare products in Canada. Its portfolio spans women's health (contraception, menopause, uterine fibroids), dermatology, allergy, neurology, pain management, and hospital specialty markets, totaling 65+ brands. The company holds exclusive Canadian commercial rights to products from international partners such as Grünenthal, Mithra, Kissei, and Sol-Gel.

Product overview

Searchlight Pharma is Apotex's Branded Medicines Division, operating as a specialty pharmaceutical company focused on acquiring and commercializing innovative healthcare products. The portfolio includes over 65 brands across key therapeutic areas including women's health (contraceptives like Nextstellis, Evra, Haloette, and IUDs; hormone therapies like Divigel and Estragyn), dermatology (Epsolay, Twyneo), allergy (Blexten, Atarax), pain management (Suvexx, Cambia, Ketalar), neurology (Valium, Nardil, Zarontin), and hospital specialty markets. The company operates a commercial brands portfolio of marketed products alongside a pipeline of products awaiting regulatory approval (including DONESTA for menopause and Twyneo for acne), and manages partnered brands distributed through international licensing agreements (including Suvexx in Europe with Orion Corporation, Pennsaid, Treximet, and Vimovo). Searchlight also holds exclusive Canadian licensing rights to several products from partners including Grünenthal (Nebido, Qutenza), Kissei Pharmaceutical (linzagolix), Mithra (DONESTA), and Sol-Gel (Twyneo, Epsolay).

Differentiator

Problem solved

Functional benefit

Products and services

• Nextstellis Combined oral contraceptive containing estetrol monohydrate and drospirenone, the first contraceptive approved globally based on estetrol (E4). For women seeking contraception.
• Evra

Quantifiable outcome

• Ranked among top 3 specialty pharmaceutical companies in Canada (post-Miravo acquisition)
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

19 partnerships are on record, tiered core and minor.

• GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 5 February 2026Apotex's Searchlight Pharma division signed an exclusive licensing agreement with Grünenthal to market Nebido (testosterone undecanoate), a long-acting injectable therapy for male hypogonadism, in Canada. Searchlight will pursue regulatory approval and market and distribute the product upon authorization. Grünenthal receives upfront payment, regulatory milestone payments, and a margin on sales. This marks Apotex's first entry into testosterone therapy and deepens an existing partnership, which also includes Qutenza (neuropathic pain patch).
• Kissei PharmaceuticalcoreOEM/ Whitelabel/ Licensing Partner · 7 October 2025Searchlight Pharma entered into a licensing agreement securing exclusive Canadian rights to linzagolix, an oral GnRH antagonist treatment for uterine fibroids developed by Japan's Kissei Pharmaceutical. The product is marketed as Yselty in Europe. Searchlight will lead regulatory efforts to pursue marketing authorization in Canada, where uterine fibroids affect up to 70% of women by age 50.
• GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 24 February 2025Apotex and Grünenthal signed a strategic licensing agreement granting Apotex exclusive Canadian rights to Qutenza, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Searchlight Pharma will pursue regulatory approval and market the product in Canada, with Grünenthal receiving upfront, regulatory milestone, and royalty payments.
• Mithra PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2023Mithra and Searchlight Pharma signed a licensing and supply agreement for Canadian rights to DONESTA, a next-generation oral hormone therapy based on estetrol for menopause symptoms. Mithra receives €1.5M upfront, up to €15.55M in regulatory and sales milestones, and tiered double-digit royalties on net sales. Searchlight will file for Canadian regulatory approval in H1 2024. This is the third licensing agreement between the companies, following NEXTSTELLIS (launched Q3 2021) and HALOETTE (launched Q1 2022).
• Orion CorporationcoreChannel Partner/ Reseller/ Distributor · 15 August 2023Orion Corporation launched Suvexx (sumatriptan/naproxen sodium) in Europe under a license and supply agreement with Searchlight's subsidiary Nuvo Ireland. An amendment extended the agreement to all EU markets. Orion received an upfront payment of €600K and will pay €400K upon launch in significant EU markets, plus sales milestones and royalties. Orion is responsible for obtaining and maintaining marketing authorizations and managing commercial activities across European territories.
• Sol-Gel TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 6 June 2023Sol-Gel and Searchlight signed exclusive license agreements for TWYNEO (tretinoin + benzoyl peroxide cream for acne) and EPSOLAY (benzoyl peroxide 5% cream for rosacea) for the Canadian market. Sol-Gel could receive up to $11M in milestone payments tied to regulatory and sales achievements, plus royalties of 10-19% on net Canadian sales. The 15-year renewable agreements position both products as foundational elements of Searchlight's dermatology pipeline and portfolio.
• Gedeon RichtercoreChannel Partner/ Reseller/ Distributor · 12 May 2022Gedeon Richter and Searchlight Pharma announced Searchlight's assumption of all Canadian distribution and promotion activities for Evra, a transdermal contraceptive patch. The transition resulted from Richter's acquisition of Evra rights from Janssen Pharmaceutica (J&J) in December 2020. Evra generated CAD $12 million in sales in Canada in 2021 and remains the only transdermal contraceptive option available in Canada (approved by Health Canada since 2002).
• Gebro Pharma AGminorChannel Partner/ Reseller/ DistributorGebro Pharma AG (Switzerland) is a partner for the distribution of Pennsaid 2% and Pennsaid in their respective territories.
• Paladin LabsminorChannel Partner/ Reseller/ DistributorPaladin Labs (Canada) is a partnered brand distributor for Pennsaid in Canada.
• Vianex S.A.minorChannel Partner/ Reseller/ DistributorVianex S.A. (Greece) is a partnered brand distributor.
• Recordati S.p.A.minorChannel Partner/ Reseller/ DistributorRecordati S.p.A. (Italy) is a partnered brand distributor.
• Fagron Belgium NVminorChannel Partner/ Reseller/ DistributorFagron Belgium NV (Benelux) is a partnered brand distributor for Resultz.
• Heumann Pharma GmbH & Co. Generica KGminorChannel Partner/ Reseller/ DistributorHeumann Pharma GmbH & Co. Generica KG (Germany) is a partnered brand distributor for Lausbub.
• Reckitt Benckiser (Brands) LimitedminorChannel Partner/ Reseller/ DistributorReckitt Benckiser (UK, Ireland, Russia, Spain, Portugal) is a partnered brand distributor for FullMarks.
• SK Chemicals Co., Ltd.minorChannel Partner/ Reseller/ DistributorSK Chemicals Co., Ltd. (South Korea) is a partnered brand distributor for Suvexx.
• Currax Holdings USA LLCminorChannel Partner/ Reseller/ DistributorCurrax Holdings USA LLC (USA) is a partnered brand distributor for Treximet (the US brand name for Suvexx).
• Horizon Therapeutics plcminorChannel Partner/ Reseller/ DistributorHorizon Therapeutics plc (USA) is a partnered brand distributor for Vimovo.
• Grünenthal GmbH (ROW)minorChannel Partner/ Reseller/ DistributorGrünenthal GmbH (ROW) is a partnered brand distributor.
• Apotex Inc.coreOthersApotex Inc. completed the acquisition of Searchlight Pharma in June 2024. Searchlight operates as Apotex's Branded Medicines Division, combining Searchlight's strong specialty and innovative branded product portfolio with Apotex's market leadership in generic and biosimilar pharmaceuticals.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Knight Therapeutics: Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across women's health, oncology, and specialty therapeutics in Canada and select international markets. Directly comparable business model and target customer base to Searchlight.
• HLS Therapeutics: Canadian specialty pharma focused on acquiring and commercializing branded products in CNS, cardiology, and women's health. Operates with a similar in-licensing model targeting Canadian healthcare professionals, making it a directly comparable peer.
• Theramex: Global specialty pharmaceutical company exclusively focused on women's health, with a portfolio spanning contraception, menopause, and fertility. Direct strategic overlap with Searchlight's primary women's health focus and similar in-licensing model.
• Paladin Labs: Canadian specialty pharma (acquired by Endo International) that acquires, in-licenses, and markets branded prescription products. Adam Bulow, Searchlight's VP, spent 10 years at Paladin, and the company is a partnered brand distributor for Searchlight's Pennsaid in Canada.
• Acerus Pharmaceuticals: Canadian specialty pharmaceutical company focused on men's health (testosterone replacement) and women's health, with a similar lean operating model and Canadian commercialization footprint. Recently acquired by Aytu BioPharma.
• Cipher Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing specialty products in dermatology and hospital specialty markets. Similar in-licensing and commercialization approach, and overlapping therapeutic areas with Searchlight.

Broad incumbents

• Organon: Global women's health-focused pharmaceutical company spun out from Merck, with established franchises in contraception, fertility, and menopause. A larger incumbent operating in the same therapeutic categories that Searchlight targets.
• Endo International: Global specialty pharmaceutical company with a portfolio spanning branded specialty, generics, and sterile injectables. Owns Paladin Labs and competes in overlapping dermatology, pain, and women's health categories with Searchlight's portfolio.
• Gedeon Richter: Hungarian-headquartered specialty pharmaceutical company with a strong women's health portfolio including Evra (rights acquired from J&J). Searchlight partners with Richter for Evra distribution in Canada, and Richter competes in overlapping women's health categories.
• Bausch Health: Large diversified pharmaceutical company with a major Canadian commercial presence across dermatology, neurology, and specialty brands. Operates as a broad incumbent with overlapping therapeutic categories and Canadian market overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Searchlight Pharma